$1.63
-0.10-5.78%
Last update: Oct 30, 6:35 PM
TransCode Therapeutics Inc (RNAZ) Stock Price, Quote, News & History
RNAZNASDAQ
TransCode Therapeutics announced successful completion of Phase 1a clinical trial for TTX-MC138, showing safety and disease stabilization in patients with...
You can purchase shares of TransCode Therapeutics (NASDAQ:RNAZ) through any online brokerage.
Other companies in TransCode Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
TransCode Therapeutics has a consensus price target of $280.00.
The stock price for TransCode Therapeutics (NASDAQ: RNAZ) is $1.5165 last updated October 30, 2026 at 6:35 PM EDT.
There are no upcoming dividends for TransCode Therapeutics.
TransCode Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for TransCode Therapeutics.
TransCode Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a...
